<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061161</url>
  </required_header>
  <id_info>
    <org_study_id>2018-002173-22</org_study_id>
    <nct_id>NCT04061161</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD</brief_title>
  <acronym>ANTIOFLAM</acronym>
  <official_title>Anti-inflammatory Effects of Tiotropium in Patients With Stable COPD- A Multicenter Randomized Controlled Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the anti-inflammatory effects after 6 weeks treatment with
      tiotropium compared to placebo in patients with stable COPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Acetylcholine is the primary parasympathetic neurotransmitter in the airways, and
      induces bronchoconstriction. Since the cholinergic tone appears to be the major reversible
      component of obstruction, muscarinic receptor antagonism and bronchodilation represent the
      primary goal of anticholinergic therapy in patients with chronic obstructive pulmonary
      disease (COPD). Long-acting anticholinergic therapy is central in GOLD stage B-D, because of
      improvements in lung function, quality of life, and especially reduction of exacerbations.
      The elicited reduction in exacerbations with the long-acting muscarinic antagonist (LAMA)
      tiotropium appears larger than that of the long-acting beta agonist (LABA) salmeterol even
      when the bronchodilation is similar. In asthma too, it has been shown that the addition of
      the tiotropium to inhaled corticosteroids (ICS)+LABA combination therapy reduces the number
      of severe exacerbations. These effects on exacerbation frequency suggest that tiotropium
      might exert anti-inflammatory effects in the airways next to bronchodilatory effects. There
      are multiple animal and in vivo studies to indeed suggest an anti-inflammatory effect of
      anticholinergics.

      Such an anti-inflammatory effect of anticholinergic intervention could be clinically
      relevant; however it has not been previously demonstrated in patients with COPD.

      The investigators hypothesize that tiotropium bromide reduces the ongoing inflammation in
      patients with COPD compared to placebo. The investigators expect a decrease of TNF-alpha mRNA
      in sputum after treatment with tiotropium bromide.

      Objective: This research proposal aims to assess the anti-inflammatory effects after 6 weeks
      treatment with tiotropium compared to placebo in patients with stable COPD.

      Study design: This will be a multicenter parallel design randomized controlled double-blinded
      study.

      Study population: A total of 50 COPD patients with stable disease status will be included and
      followed for two consecutive visits.

      Intervention: COPD patients will be randomized to the treatment group (tiotropium respimat 5
      ug) or to the placebo group.

      Main study parameters/endpoints: A decrease of TNF-alpha mRNA in induced sputum will be the
      main parameter for assessing the anti-inflammatory effects of 6 week treatment with
      tiotropium in patients with stable COPD. Additionally, changes in sputum cell differentials
      and other cytokine parameters (protein, mRNA,LTB4), blood cell differentials, CRP, and
      cytokine parameters, health related quality of life (CCQ, CAT) will be assessed as well as
      changes in post-bronchdilator FEV1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a multicenter parallel design randomized placebo controlled double-blinded study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in concentration of TNF-alpha (mRNA level) in induced sputum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in TNF-alpha mRNA level in induced sputum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of sputum cell differentials in induced sputum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in sputum cell differentials (% of total cells) in induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of LTB4 level in induced sputum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in LTB4 level (pg/ml) in induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of cytokine protein level in induced sputum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in cytokine protein levels (IL-8,IL-6,MCP-1, TNF-a, MIP-1beta,TGF-beta,MPO, ECP; pg/ml) in induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of cytokine mRNA level in induced sputum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in cytokine mRNA levels of IL-8,IL-6,MCP-1, TNF-a, MIP-1beta,TGF-beta,MPO, ECP in induced sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of cell differentials + CRP in blood serum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in cell differentials (10^9/L) +CRP (mg/L) in blood serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration cytokine protein level in blood serum</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a change in cytokine protein levels (IL-6,TNF-a,siCAM; pg/ml) in blood serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life (CCQ, CAT questionnaires)</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>To assess whether 6 weeks treatment with tiotropium elicts anti-inflammatory effects compared to placebo in patients with stable COPD, as measured by a changein health related quality of life (CCQ and CAT questionnaires)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Differences in gene expression measured in sputum samples</measure>
    <time_frame>6 week treatment duration</time_frame>
    <description>RNA-sequencing of sputum samples</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Tiotropium respimat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium respimat 2.5mcg two actuations once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo respimat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo respimat two actuations once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks</description>
    <arm_group_label>Placebo respimat</arm_group_label>
    <arm_group_label>Tiotropium respimat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Men or women, age &gt;= 40 years.

               -  A diagnosis of COPD according to the criteria of the GOLD organization

               -  Post-bronchodilator FEV1 / FVC ratio &lt; 70% (ERS equations) and
                  post-bronchodilator FEV1 &lt; 80%pred.

               -  A smoking history of &gt; 10 pack years.

               -  post-bronchodilator FEV1 &gt; 1.5 Litres and ability to produce sputum after
                  hypertonic saline induction.

               -  No upper or lower respiratory tract infection in the last 4 weeks necessitating
                  antibiotic treatment or consisting of quite probable viral etiology.

               -  Being in a stable phase of COPD, as judged by the investigator. No courses of
                  systemic steroids or antibiotics for respiratory problems last 4 weeks

               -  The participant needs to be able to understand the Dutch language

               -  Signed and dated informed consent obtained before any study related procedures
                  (including withdrawal of concomitant medication) are conducted.

        Exclusion Criteria:

          -  • Treatment with immune-modulating agents for any disease, including leuktriene
             receptor antagonists,

               -  Treatment with long-acting anticholinergics &lt;4 weeks before the start of the
                  study.

               -  Treatment with corticosteroids &lt;4 weeks before the start of the study.

               -  Targeted lung denervation therapy in the past.

               -  Concomitant diagnosis of asthma.

               -  Any significant other pulmonary disease or disorder (e.g. known
                  alpha1-antitrypsine deficiency, significant bronchiectasis), as judged by the
                  investigator.

               -  Narrow angle glaucoma.

               -  Azithromycine maintenance treatment.

               -  Active malignant disease (at least 5 years malignant disease-free)

               -  Other significant disease or disorder (like cardiovascular, gastrointestinal,
                  liver, renal, neurological, musculoskeletal, endocrine, metabolic (including
                  diagnosed diabetes), malignant, psychiatric, major physical impairment), which,
                  in the opinion of the investigators may either put the patient at risk because of
                  participation in the study, or may influence the results of the study, or the
                  patient's ability to participate in the study.

               -  Females of childbearing potential without an efficient contraception unless they
                  meet the following definition of post-menopausal: 12 months of natural
                  (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH &gt;40
                  mIU/mL or the use of one or more of the following acceptable methods of
                  contraception:

                    1. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy).

                    2. Hormonal contraception (implantable, patch, oral, injectable).

                    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/cream/suppository.

                    4. Continuous abstinence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wouter van Geffen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical centrum Leeuwarden, Department of pulmonology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedikt Ditz, MD</last_name>
    <phone>+31625649905</phone>
    <email>l.b.ditz@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huib A.M. Kerstjens, MD PhD</last_name>
    <phone>+31503612080</phone>
    <email>h.a.m.kerstjens@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedikt Ditz, MD</last_name>
      <phone>0037625649905</phone>
      <email>l.b.ditz@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Huib Kerstjens, Prof, Dr, MD</last_name>
      <phone>0031 50 361 0280</phone>
      <email>h.a.m.kerstjens@umcg.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Hirmann</last_name>
      <phone>003158-2866427</phone>
      <email>Petra.Hirmann@ZNB.NL</email>
    </contact>
    <contact_backup>
      <last_name>Wouter van Geffen, Dr, MD</last_name>
      <phone>003158- 2866190</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Bathoorn E, Liesker J, Postma D, Koëter G, van Oosterhout AJ, Kerstjens HA. Safety of sputum induction during exacerbations of COPD. Chest. 2007 Feb;131(2):432-8.</citation>
    <PMID>17296644</PMID>
  </reference>
  <reference>
    <citation>Brightling CE, Monterio W, Green RH, Parker D, Morgan MD, Wardlaw AJ, Pavord D. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med. 2001 Dec;95(12):999-1002.</citation>
    <PMID>11778799</PMID>
  </reference>
  <reference>
    <citation>Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006 May 9;7:73. Review.</citation>
    <PMID>16684353</PMID>
  </reference>
  <reference>
    <citation>Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012 Sep 27;367(13):1198-207. Epub 2012 Sep 2.</citation>
    <PMID>22938706</PMID>
  </reference>
  <reference>
    <citation>Kistemaker LE, Bos IS, Menzen MH, Maarsingh H, Meurs H, Gosens R. Combination therapy of tiotropium and ciclesonide attenuates airway inflammation and remodeling in a guinea pig model of chronic asthma. Respir Res. 2016 Feb 4;17:13. doi: 10.1186/s12931-016-0327-6.</citation>
    <PMID>26846267</PMID>
  </reference>
  <reference>
    <citation>Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015 Mar;36(3):164-71. doi: 10.1016/j.tips.2014.11.005. Epub 2014 Dec 13. Review.</citation>
    <PMID>25511176</PMID>
  </reference>
  <reference>
    <citation>Kistemaker LE, Oenema TA, Meurs H, Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012 Nov 27;91(21-22):1126-33. doi: 10.1016/j.lfs.2012.02.021. Epub 2012 Mar 3. Review.</citation>
    <PMID>22406302</PMID>
  </reference>
  <reference>
    <citation>Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J. 2009 Apr;33(4):778-84. doi: 10.1183/09031936.00115308. Epub 2009 Jan 7.</citation>
    <PMID>19129278</PMID>
  </reference>
  <reference>
    <citation>Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, Kesten S, Wedzicha JA. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007 Sep;30(3):472-8. Epub 2007 May 15.</citation>
    <PMID>17504798</PMID>
  </reference>
  <reference>
    <citation>Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.</citation>
    <PMID>18836213</PMID>
  </reference>
  <reference>
    <citation>&quot;Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.&quot; Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha and Alvar Agusti. Eur Respir J 2017; 49: 1700214. Eur Respir J. 2017 Jun 22;49(6). pii: 1750214. doi: 10.1183/13993003.50214-2017. Print 2017 Jun.</citation>
    <PMID>28642306</PMID>
  </reference>
  <reference>
    <citation>Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.</citation>
    <PMID>21428765</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Huib A.M. Kerstjens</investigator_full_name>
    <investigator_title>Full professor pulmonology; Head of department of Pulmonology and Tuberculosis; Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tiotropium</keyword>
  <keyword>Anti-inflammatory effects</keyword>
  <keyword>TNF-alpha mRNA in induced sputum</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

